Establishing a Hematopoietic Stem Cell Transplantation Unit : A Practical Guide.

Intro -- Preface -- Contents -- Contributors -- Chapter 1: Global Perspectives on Hematopoietic Stem Cell Transplants (HSCTs) -- Introduction -- WHO, Worldwide Network for Blood and Marrow Transplantation (WBMT), and Activity Surveys -- Global WBMT Data Collection System -- HSCT Activity in the Global Context -- Consequences -- References -- Chapter 2: General Principles of HSCT -- Introduction -- Engraftment -- Graft-Versus-Host Disease (GVH-D) -- Supportive Care -- Recurrence of the Disease -- Donor Lymphocyte Infusion (DLI) -- Important Developments in HSCT -- Autologous HSCT -- T-Cell Depletion -- Unrelated HSCT -- Source of Stem Cells -- Efforts to Reduce Morbidity and Mortality -- Reduced-Intensity Conditioning (RIC) -- Autologous Followed by Allogeneic HSCT (Auto-Allo) -- HSCT in Patients with Refractory or Relapsed Disease -- Alternative Donor Transplants -- Haploidentical HSCT -- Post-Cyclophosphamide Transplants -- Cord Blood -- HSCT for Non-malignant Diseases -- Treatment of Rejections After HSCT -- Treatment of Relapses After HSCT for Malignant Diseases -- Indications for Transplant -- Conclusions -- References -- Chapter 3: The HSCT Program Structure: Minimal Requirements -- Introduction -- Transplant Program Structure -- Minimal Requirements for Starting HSCT Programs -- Infrastructure -- Ancillary Laboratory Services -- Ancillary Clinical Services -- Personnel -- Quality and Data Management -- Beyond Minimal Requirements for HSCT Programs -- Conclusions -- References -- Chapter 4: Inpatient HSCT Unit -- Introduction -- Patient Area -- References -- Chapter 5: Outpatient HSCT Unit -- Introduction -- Clinic Rooms -- Procedure Rooms -- Infusion Area -- Venous Access -- Educator -- Transplant Coordinator -- Personnel -- Conclusions -- References -- Chapter 6: Indications for Hematopoietic Stem Cell Transplantation in Children.

Introduction -- Hematological Malignancies -- Acute Lymphoblastic Leukemia (ALL) -- Indications for HSCT in First Complete Remission (CR1) -- Indications for HSCT in Second (CR2) or Subsequent Complete Remission -- Acute Myeloid Leukemia (AML) -- Indications for HSCT in First Complete Remission (CR1) -- Indications for HSCT in Second (CR2) or Subsequent Complete Remission -- Acute Promyelocytic Leukemia (APL) -- Chronic Myeloid Leukaemia (CML) -- Myelodysplastic Syndromes and Myeloproliferative Neoplasms -- Pediatric Lymphomas -- Hodgkin Lymphoma -- Non-Hodgkin Lymphoma (NHL) -- Non-malignant Disorders -- Primary Immune Deficiencies -- Hemoglobinopathies Disorders -- Thalassemia Major -- Sickle Cell Disease -- Acquired Severe Aplastic Anemia -- Constitutional Bone Marrow Failure Syndromes -- Fanconi Anemia -- Dyskeratosis Congenita -- Diamond-Blackfan Anemia -- Severe Congenital Neutropenias and Inherited Thrombocytopenias -- Inborn Errors of Metabolism -- Solid Tumors -- References -- Chapter 7: Indications for Allogeneic Hematopoietic Stem Cell Transplantation in Adults -- Introduction -- Disease-Specific Indications for Allogeneic Transplantation -- Malignant Hematological Conditions -- Leukemias -- Acute Myeloid Leukemia -- Recommendations: -- Myelodysplastic Syndrome -- Recommendations -- Acute Lymphoblastic Leukemia -- Recommendations -- Chronic Myelogenous Leukemia -- Recommendations -- Chronic Lymphocytic Leukemia -- Recommendations -- Myeloproliferative Neoplasms (Other than CML) -- Recommendations -- Lymphomas -- Diffuse Large B-Cell Lymphoma -- Recommendations -- Follicular Lymphoma -- Recommendations -- Mantle Cell Lymphoma -- Recommendations -- Mature T-Cell and Natural Killer (NK)/T-Cell Lymphomas -- Recommendations -- Hodgkin Lymphoma -- Recommendation -- Plasma Cell Dyscrasias -- Multiple Myeloma -- Recommendation.

Non-malignant Hematological Conditions -- Aplastic Anemia -- Acquired (or Idiopathic) Aplastic Anemia -- Recommendations -- Sickle Cell Disease -- Recommendations -- Thalassemia -- Recommendations -- Other Indications -- Conclusion -- References -- Chapter 8: Immunogenetics Laboratory -- Introduction -- Staff and Facilities -- Services to the Transplant Center -- Services and Specific Techniques in the Immunogenetics Laboratory -- HLA Typing Technologies -- Resolution Levels and Ambiguities -- Serology -- PCR-SSP -- PCR-SSO -- Sequence-Based Typing (SBT) -- Antibody Testing -- CDC -- Flow panel reactive antibodies (PRA) -- Bead Arrays -- Chimerism and Engraftment Monitoring -- Short Tandem Repeats (STRs) -- Quantitative Real-Time PCR (qPCR) -- External Proficiency Testing -- Laboratory Accreditation -- Summary -- References -- Chapter 9: Stem Cell Source -- Introduction -- Collection -- Processing -- Distribution and Delivery -- Administration to Patient -- Conclusion and Perspectives -- References -- Chapter 10: Donor/Recipient Selection, Work-Up, and Safety -- Introduction -- Patient Selection and Work-Up -- Underlying Disease and Remission Status -- Patient Clinical Assessment and Comorbidities -- Donor Selection, Work-Up, and Safety -- Donor Selection -- Responsibility for Donor Selection, Informed Consent, Medical Evaluation, and Donor Clearance -- Donor Evaluation and Work-Up -- Personal History and Physical Examination -- Laboratory Examination -- Other Examinations -- Adverse Events Associated with HSC Donation and Donor Safety -- Long-term Follow-up after HSC Donation -- Subsequent Donations -- Pediatric Donors -- References -- Chapter 11: Essential Requirements for Setting Up a Stem Cell Processing Laboratory -- Introduction -- Establishing a Quality Management System -- Laboratory Design -- Process Flow -- Processing Capabilities.

Cryopreservation and Storage -- Allogeneic Capabilities -- Cellular Therapy Product Characterization -- Personnel -- Equipment -- Supplies and Reagents -- Clinical Correlates -- Traceability, Vigilance, and Quarantine -- Regulation and Accreditation of Stem Cell Laboratories -- Conclusions -- References -- Chapter 12: Supportive Care -- Introduction -- Intravenous Access -- Intensive Care Access -- Antiemetic Support -- High Emetic Risk: Prevention of Acute and Delayed Emesis -- Treatment for Breakthrough Chemotherapy-Induced Nausea and Vomiting -- Prevention of Total Body Irradiation (TBI)-Induced Emesis -- Mucositis -- Oral Mucositis -- Gastrointestinal Mucositis -- Nutritional Support -- Diet in HSCT Recipients with Gastrointestinal GVH-D -- Pain Control -- Management of Drug Toxicity -- Establishment of Anti-infective Policies -- Further Reading -- Chapter 13: Transfusion -- Introduction -- Considerations Regarding Blood Products for Transfusion -- Preparation of Autologous Blood Transfusion for Bone Marrow Harvest in a Bone Marrow Donor -- ABO Blood Type in Transplantation -- Transplantation with ABO Blood Type Compatibility -- Transplantation with ABO Blood Type Incompatibility -- Major Incompatibility -- Minor Incompatibility -- Major/Minor Incompatibility -- Blood Transfusion after Engraftment -- Transfusion in Transplantation with Rh Incompatibility -- Other Blood Type Incompatibilities (Irregular Antibody- Positive Cases) -- Application of Platelet Transfusion in Transplant Patients -- Prediction and Evaluation of Transfusion Efficacy -- Tests when the Planned Transplantation Patient is Anti-HLA Antibody-Positive -- Tests when the Donor is Anti-HLA Antibody-Positive -- Preparation of Blood Type Sheet for Transplantation -- Conclusion -- References -- Chapter 14: Laboratory Support -- Introduction -- Serologic Testing of Blood Groups.

Infectious Disease Testing -- Testing Methods for Use in Bacterial Infections -- Testing Methods for Use in Fungal Infections -- Testing Methods for Use in Viral Infections -- Therapeutic Drug Monitoring -- Immunophenotyping for CD34+ Cell Enumeration -- Minimal Residual Disease Testing -- References -- Chapter 15: Quality Management -- Introduction -- Why is a Quality Management System Important? -- The Quality Management System -- Establishing a QMS -- Regulations -- Responsibilities -- Components of a Quality Management System -- People and Organization -- Training and Education -- Competency -- Agreements -- Documentation and Record-Keeping -- Quality Management Plan -- Standard Operating Procedures -- Minimal Elements Required in Each SOP -- Records -- Document Control -- Product Tracking and Traceability -- Audits -- Auditing the Improvements -- Validation and Verification -- Investigation and Reporting of Non-conformances, Adverse Events, Complaints, and Adverse Reactions -- Complaints -- Recall -- Conclusion -- References -- Chapter 16: Long-Term Follow-Up Program -- Introduction -- Late Complications of HSCT -- LTFU Care Models -- Integrated Care Model -- Consultative Care Model -- Transitional Care Model -- Shared Care Model -- Organization and Implementation of an LTFU Program -- Types of Services Provided -- Treatment Summary and Survivorship Care Plan -- Physician- Versus Non-Physician-Led LTFU Programs -- Conclusion -- References -- Chapter 17: Hematopoeitic Stem Cell Transplantation Outcome Data Management: Importance of Establishing an Institutional Database -- Introduction -- Planning an HSCT Registry -- Registry Design -- Data Elements -- Data Sources -- Ethics, Data Ownership, and Privacy -- Informed Consent for Registries -- Confidentiality and Legal Concerns for Providers, Manufacturers, and Health Plans.

Data Collection and Quality Assurance.

Description based on publisher supplied metadata and other sources.

Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries.